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BACKGROUND. Sporadic vascular malformations (VMs) are complex congenital
anomalies of blood vessels that lead to stroke, life-threatening bleeds, disfigurement,
overgrowth, and/or pain. Therapeutic options are severely limited, and multidisciplinary
management remains challenging, particularly for high-flow arteriovenous malformations
(AVM).
METHODS. To investigate the pathogenesis of sporadic intracranial and extracranial VMs
in 160 children in which known genetic causes had been excluded, we sequenced DNA
from affected tissue and optimized analysis for detection of low mutant allele frequency.
RESULTS. We discovered multiple mosaic-activating variants in 4 genes of the RAS/MAPK
pathway, KRAS, NRAS, BRAF, and MAP2K1, a pathway commonly activated in cancer and
responsible for the germline RAS-opathies. These variants were more frequent in high-flow
than low-flow VMs. In vitro characterization and 2 transgenic zebrafish AVM models that
recapitulated the human phenotype validated the pathogenesis of the mutant alleles.
Importantly, treatment of AVM-BRAF mutant zebrafish with the BRAF inhibitor vemurafinib
restored blood flow in AVM.
CONCLUSION. Our findings uncover a major cause of sporadic VMs of different clinical
types and thereby offer the potential of personalized medical treatment by repurposing
existing licensed cancer therapies.
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BACKGROUND. Sporadic vascular malformations (VMs) are complex congenital anomalies of blood vessels that lead to 
stroke, life-threatening bleeds, disfigurement, overgrowth, and/or pain. Therapeutic options are severely limited, and 
multidisciplinary management remains challenging, particularly for high-flow arteriovenous malformations (AVM).
METHODS. To investigate the pathogenesis of sporadic intracranial and extracranial VMs in 160 children in which known 
genetic causes had been excluded, we sequenced DNA from affected tissue and optimized analysis for detection of low 
mutant allele frequency.
RESULTS. We discovered multiple mosaic-activating variants in 4 genes of the RAS/MAPK pathway, KRAS, NRAS, BRAF, and 
MAP2K1, a pathway commonly activated in cancer and responsible for the germline RAS-opathies. These variants were more 
frequent in high-flow than low-flow VMs. In vitro characterization and 2 transgenic zebrafish AVM models that recapitulated 
the human phenotype validated the pathogenesis of the mutant alleles. Importantly, treatment of AVM-BRAF mutant 
zebrafish with the BRAF inhibitor vemurafinib restored blood flow in AVM.
CONCLUSION. Our findings uncover a major cause of sporadic VMs of different clinical types and thereby offer the potential of 
personalized medical treatment by repurposing existing licensed cancer therapies.
FUNDING. This work was funded or supported by grants from the AVM Butterfly Charity, the Wellcome Trust (UK), the Medical 
Research Council (UK), the UK National Institute for Health Research, the L’Oreal-Melanoma Research Alliance, the European 
Research Council, and the National Human Genome Research Institute (US).
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Results
Twenty-five patients with high-flow and 135 patients with low-flow 
VMs, in whom known VM-related pathogenic variants had previous-
ly been excluded (Methods), were investigated to identify the cause 
of the clinical phenotype. Using deep next-generation sequencing 
of affected tissue, known or predicted pathogenic variants in RAS/
MAPK pathway genes were identified in 9 of the 25 patients with 
AVMs (Tables 1 and 2 and Figure 3) and confirmed by a second meth-
od. Identified variants were in KRAS (n = 4) and BRAF (n = 1), encod-
ing key proximal components of the RAS/MAPK signaling pathway, 
known to be pathogenic, but previously undescribed as causal in any 
type of VM. In addition, a cluster of variants was identified in exon 
2 of MAP2K1 (n = 4), confirming a hot spot very recently reported 
in extracranial AVM, but not known prior to our study (9), and add-
ing 1 small intragenic deletion (c.159_173del, p.[F53_Q58delinsL]) 
(Table 2 and Figure 3) to the allelic spectrum. Variant allele frequen-
cies ranged from 3% to 26% in affected tissue, but with no detectable 
variant in paired blood samples where these were available (n = 4/9, 
Table 2). One KRAS-variant patient had a sporadic AVM restricted 
to the intracranial cavity; this patient presented with an intracranial 
hemorrhage at the age of 13. The other 8 RAS/MAPK variant patients 
had AVMs centred in the skin or soft tissues at various anatomical 
sites, with intracranial extension documented in 2 (Table 1).
Of the 135 patients with low-flow VMs, 5 had mosaic RAS 
gene variants, 4 in KRAS and 1 in NRAS, known to be pathogen-
ic. Variants were present in each affected tissue tested and were 
consistent within an individual, with a variant allele load of 3% to 
29%, but undetectable in blood (n = 4/5, Table 2). These patients 
exhibited a spectrum of phenotypic manifestations, as is typical 
of mosaic disorders (Table 1).
Introduction
Sporadic vascular malformations (VMs) are congenital malforma-
tions of blood vessels with high associated morbidity and limited 
treatment options (Figure 1 and Figure 2). VMs have traditionally 
been divided into diagnostic groups according to anatomical site 
(intracranial versus extracranial) and flow characteristics (high 
versus low), with detailed subclassification incorporating multiple 
historical diagnostic labels (1). In high-flow, or arteriovenous, mal-
formations (AVM), direct complex interconnections between arter-
ies and veins without the normal interposed small-bore capillary 
network permit dangerous flow of high-pressure arterial blood into 
thin-walled veins, leading to bleeds or stroke. In low-flow, capillary 
and/or venous malformations, interconnections between anatomi-
cally abnormal capillaries and/or veins can lead to sludging of blood, 
perilesional tissue anoxia, thrombosis, and overgrowth. Application 
of next-generation sequencing to a range of sporadic syndromes fea-
turing VMs has rapidly established the paradigm that such disorders 
are commonly caused by postzygotic variants activating key cellular 
growth pathways (2–11). Variants overlap with those documented in 
cancer, but the allelic spectra may differ. Accurate genotype-based 
stratification of affected patients has begun to improve prognosti-
cation and, in conditions affecting the PI3K/AKT/MTOR signal-
ing pathway, has led to early clinical trials of targeted therapies (12, 
13). Despite these discoveries, however, a substantial proportion of 
patients have no mutations in known associated genes (9, 14, 15). 
We sought to address this issue using ultradeep next-generation 
sequencing and bioinformatic analyses aimed at detection of low 
mutant allele frequency in affected tissue. Here, we discover that 
multiple mosaic-activating variants in 4 genes of the RAS/MAPK 
pathway cause VM and model therapy in an animal model.
Figure 1. A broad clinical spectrum of 
VMs in somatic RAS/MAPK mutations. 
Inexorable enlargement of high-flow 
AVMs with age, affecting the face and 
leading to loss of vision in the right eye 
(A–D), and affecting the right ear helix 
and posterior auricular soft tissues 
leading to eventual resection of the helix 
(E–G). Varied clinical examples of the 
spectrum of high-flow VMs (AVMs) of 
the temple, left leg/buttock, and left 
face (H and I). Segmental overgrowth of 
the left arm, chest wall, and breast with 
a colocalized low-flow VM, detectable by 
a uniform brownish-pink macular capil-
lary malformation and superimposed 
scattered telangiectasia, with clear 
midline demarcation (J–L). Segmental 
overgrowth of the right arm and hand, 
with a colocalized uniform brownish-pink 
capillary malformation with super imposed 
scattered telangiectasia (M and N).
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regulated by mechanisms similar to those in humans (17), and blood 
flow through the vasculature is clearly visible by 2 days of develop-
ment (Supplemental Video 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI98589DS1). We 
injected separately BRAFV600E and MAPK2K1Q58del expressed from a 
pan-endothelial promoter, fli1a, into single-cell zebrafish embryos 
to generate postzygotic expression of BRAFV600E or MAPK2K1Q58del 
in vessels that, as in the patients, is expressed in a mosaic fashion 
(Figure 5, A and B). For some animals, both BRAF and BRAFV600E 
expression led to shortening along the anterior-posterior axis, as 
reported previously in zebrafish with high MAPK expression, and 
these were removed from the analysis (Supplemental Figure 1) (18, 
19). Notably, BRAFV600E, but not expression of WT BRAF, led to dis-
ordered vessel formation, leading to severely impeded blood flow, 
and recapitulated the clinical features of patient VMs (Figure 5, C–E, 
and Supplemental Video 1). Interestingly, these VMs formed pref-
erentially in the caudal vein vascular plexus (20). Mosaic expres-
sion of MAP2K1Q58del, but not WT MAP2K1, also generated VM (n = 
5/37) (Figure 5G). Zebrafish with established VM were then treated 
for 2 days with a low, continuous dose of vemurafenib (0.1 μM), the 
approved anticancer BRAF inhibitor, and assessed by blind scoring 
for improved blood flow (Figure 5F). Strikingly, almost all vemu-
rafenib-treated zebrafish exhibited improved blood flow (Figure 
5F and Supplemental Video 1). In contrast, drug treatment had no 
effect on control zebrafish, and only a minority of BRAFV600E VMs 
demonstrated improved blood flow spontaneously. These impor-
tant results of improvement in phenotype from RAS-RAF-MAPK–
targeted therapy in an animal model echo recent murine models of 
VM ameliorated by targeted pathway inhibition of the PI3K/AKT/
MTOR pathway (21, 22).
Structural modeling was undertaken of the 4 mosaic vari-
ants detected in exon 2 of the MAP2K1 gene, 2 identical missense 
variants (p.[K57N]), and 2 small intraexonic deletions removing, 
respectively, codons 53–58 (novel c.159_173del, p.[F53_Q58delin-
sL]) and 58–62 (c.173_187del, p.[Q58_E62del]) (Uniprot Q02750.2 
(MP2K1_HUMAN). All were found to affect helix A in the 3D pro-
tein structure (residues 44–58). The deletions of residues 53–58 
and 58–62 are predicted to affect the integrity of helix A, and K57 
is a critical amino acid involved in a hydrogen bond interaction 
with the backbone of a β strand at the active site (Figure 3C), a crit-
ical 3D structure stabilizing interaction. Numerous interactions 
involving Q46, R49, L50, F53, K57, V60, and the rest of the kinase 
domain were found in the inhibited form of MAP2K1 (Figure 3C), 
consistent with critical involvement of helix A in protein function. 
Helix A forms an integral part of the negative regulatory region of 
kinase function (16), and these variants are therefore predicted to 
destabilize the conformation of the inactive state.
Transient overexpression of MAP2K1 and BRAF mutants in 
HEK293T cells led to increased phosphorylation of ERK com-
pared to either overexpression of corresponding WT genes or 
to mock-transfected controls at 24 hours (Figure 4, A and B). 
Overexpression of 2 of the same mutants in HUVEC led to dis-
ruption and disordering of spontaneous vascular tube formation 
between 6 and 24 hours compared with mock-transfected con-
trols (Figure 4C), with significant reductions in mean number of 
master junctions, total vascular tube length, and total mesh area 
(Figure 4, D and E).
Two zebrafish models of VM were then developed to validate 
our findings in vivo and to serve as a platform for screening of poten-
tial drug treatments. Artery and vein development in zebrafish are 
Figure 2. Imaging of sporadic VMs secondary to mutations in MAPK pathway genes demonstrating involvement of all blood vessel sizes. (A) 
Lateral image from a digitally subtracted angiogram showing a leash of small, abnormal vessels shunting through a dense capillary bed to early fill-
ing veins. (B) Axial contrast-enhanced fat-saturated T1 weighted MRI image showing a grossly enlarged right pinna and thickened posterior auricular 
soft tissues. The abnormal tissue is filled with multiple signal voids, representing enlarged abnormal vessels. The pinna enhances avidly. (C) Lateral 
image from a digitally subtracted angiogram, with the catheter tip in the grossly enlarged left internal maxillary artery, which supplies a leash of 
abnormal high-flow vessels in the face. (D) Thermography of low-flow VMs with overgrowth of the left chest wall and arm demonstrates increased 
temperature (shown in magenta) compared with the right-sided structures (E), and in the right forearm and thumb compared with the left (F). 3D 
reconstruction of an abdominal CT angiogram demonstrating multifocal vascular disease, with severe stenoses of the descending aorta, coeliac axis, 
superior mesenteric artery origin, and right renal artery (E).
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in KRIT1 (24), CCM2 (25), and PDCD10 (26); however, malforma-
tions themselves require a somatic “second hit” (27). The same par-
adigm of an inherited genetic diathesis interacting with a somatic 
mutation applies to heritable extracranial low-flow malformations 
caused by mutations in TEK (10) and GLMN (28, 29) and heritable 
(high-flow) AVMs associated with mutations in PTEN, ACVR1, ENG, 
RASA1 (30, 31). The same mechanism is also likely in the recently 
described gene for CM-AVM syndrome EPHB4 (32). Known causes 
of sporadic VMs are postzygotic mutations in TEK (10, 11), AKT1 (2), 
PIK3CA (7), GNAQ (3, 4), GNA11 (4), and MAP3K3 (8) in low-flow 
VMs and recently described MAP2K1 mutations in high-flow extra-
cranial malformations (Figure 6). Thus, there is a pattern of milder 
predisposing mutations in the germline requiring a second hit to 
lead to phenotype and more severe mutations leading directly to a 
phenotype only seen as postzygotic hits. Our discovery that RAS/
MAPK VM mutations are strong activators of the MAPK signaling 
pathway and overlap with the cancer allele spectrum is in line with 
the hypothesis that lethal genes survive by mosaicism (33).
Discussion
We discovered mosaic-activating variants in oncogenes at several 
levels of the RAS/MAPK signaling pathway as a major cause of 
sporadic VMs and particularly of the clinically high-risk group of 
AVMs. This discovery identifies the RAS/RAF/MAPK pathway 
as a major cause of sporadic VMs and opens the door to repur-
posing of targeted medical therapies on a personalized medicine 
basis. The pathogenicity of these variants is supported by several 
lines of evidence, including the well-established pathogenicity of 
the BRAF, KRAS, and NRAS variants in other disorders and tis-
sues, the mosaic occurrence of these variants in the lesions and 
their absence in peripheral blood, and the existence of a hotspot 
of MAP2K1 variants in the Catalogue Of Somatic Mutations In 
Cancer (COSMIC) database (http://cancer.sanger.ac.uk/cosmic), 
comprising 65 tumor variants from F53 to E62.
Several genetic causes of human inherited and sporadic VM 
are already known (23). Inherited susceptibility to cerebral cavern-
ous (low-flow) malformations is conferred by germline mutations 
Table 1. Phenotypic characterization of 15 individuals with MAPK pathway variants and sporadic VMs
Patient no. Age Phenotype
1 19 years High flow; AVM left face, recurrent bleeding, progressive enlargement
2 33 years High flow; AVM right face, recurrent bleeding, progressive enlargement
3 12 years High flow; AVM right face, recurrent bleeding, loss of vision right eye, progressive enlargement
4 24 years High flow; AVM left buttock, recurrent bleeding, progressive enlargement
5 20 years High flow; AVM right temple area, recurrent bleeding, progressive enlargement
6 9 years High flow; AVM right external ear, and posterior auricular soft tissues
7A 24 years High flow. Deep vessel mixed arterial and venous malformation of the left posterior chest wall and overlying skin. Extensive asymmetric linear verrucous 
keratinocytic epidermal nevus of the back with a few areas suggestive of sebaceous nevus. Hypertension caused by bilateral renal artery stenosis, with long 
strictures of the descending aorta, coeliac axis, and superior mesenteric artery also abnormal. Surgery for removal of symptomatic spinal root plexiform 
neurofibromas on 2 occasions and an intraspinal lipoma on 1 occasion. Postsurgical kyphoscoliosis. Mutations in NF1 and PTEN genes excluded.
8 13 years High flow; AVM left external ear, posterior auricular soft tissues, intracranial extension, progressive enlargement
9 14 years High flow. AVM in the right frontal lobe, supplied by a branch of the right anterior cerebral artery. Presented aged 13 with intracranial hemorrhage and 
intraventricular extension, previously well. Required craniotomy and resection of AVM.
10 18 years Low flow. Mild overgrowth of right arm and shoulder girdle from age 10, with prominent superficial veins and reticulate capillary malformation on the right 
upper arm. No deep vessel malformation detectable, chronic pain in palpably warm right hand, with brownish-pink uniform capillary malformation and 
scattered telangiectasia.
11 39 years Low flow. Subtle congenital right foot overgrowth that gradually progressed and extended to buttock by second decade. Prominent superficial veins and 
dependent edema from 20 years old, still progressing. No capillary malformation.
12 14 years Low flow. Nonprogressive congenital mild overgrowth with colocalized capillary malformation of the left arm, hand, shoulder girdle, chest wall, and breast 
with clear midline demarcation. The capillary malformation was uniform brownish-red and punctuated by telangiectasia with a pale halo. The overgrown area 
was painful and palpably warm, but hematological indices and deep vessels were normal.
13 7 years Low flow. Overgrowth of the third and fourth fingers on the right hand (length and breadth), forearm smaller in girth on right than left. Venous prominence 
on the right forearm and hand, and confluence of hyperpigmentation and increased vascularity of the right chest, shoulder and back. Pain on palpation of 
the right third finger. One fracture of the left distal radius. Skeletal x-rays showed enlargement of his phalanges and metacarpals of the right third and fourth 
fingers and multifocal osteal lesions described as lucent, expansile, and lytic lesions involving the fingers, foot, tibia, humerus, femur, and clavicle on the 
right. Needle biopsy and surgical pathology of the right tibia, including small fragments of bone associated with scant fibrous tissue and skeletal muscle, 
which showed spindle and giant cell proliferation diagnosed as nonossifying fibroma. Clinical genetic testing of the germline with a neurofibromatosis panel 
and whole-exome sequencing were negative.
14 10 months Low flow. Widespread linear keratinocytic epidermal nevus in a Blaschko-linear distribution, localized to the right side except on the midback where there is 
a small streak on the left. Affects trunk and leg but not head. Moderate right-sided hemihypertrophy mainly affecting the leg. Capillary VM apparent on right 
foot and buttock. Nevus simplex on glabella and nape of neck.
15 36 years Low flow. Keft lower limb hypertrophy requiring epiphyseal fusion, lymphedema, varicose veins with previous recurrent deep vein thrombosis and cutaneous 
VM. Complicated by recurrent cellulitis and left hip pain.
ASee Supplemental Table 5.
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cases. Although several mosaic disorders have been described in 
association with postzygotic activating variants in RAS oncogenes, 
VMs have not been described in those phenotypes (40–46). Arte-
rial abnormalities have been described in association with epider-
mal nevi, but without genotype data (47–49). Interestingly, post-
natal somatic second-hit RAS and RAF gene family variants have 
been described in the small acquired vascular tumors pyogenic 
granulomas, arising on a background of a postzygotic GNAQ-vari-
ant congenital capillary malformation (50). In these cases, RAS 
variants were not the cause of the underlying VM, but consistent 
with somatic RAS variants leading to tumors of many types.
These findings are particularly important in the context of the 
lack of effective therapy for complex VMs, particularly for AVMs. 
Embolization and surgical intervention are not always possible for 
safety reasons and, where possible, can have limited short-term 
results due to very frequent localized recanalization and recur-
rence or be associated with disfiguring results. Identification of 
In silico protein-interaction analysis (34) of the full spectrum 
of genes associated with VMs, including our new findings, demon-
strates a strong network of functional interaction among the gene 
products (Supplemental Figure 2). This aligns with recent mechanis-
tic work on VMs secondary to germline variants in CCM2, PCD10, 
and KRIT1, which drive VMs by increasing MAP3K3 (MEKK3) sig-
naling in endothelial cells (35). MAP3K3 is essential for the develop-
ment of embryonic cardiovascular systems in mice (36) and zebra-
fish (37) and is considered a critical nexus between the congenital 
cavernous malformation complex and downstream signaling path-
ways (35, 37, 38), such as those mediated by Rho signaling (38), p38 
MAPK (39), and MEK5/ERK5 (37, 39). We hypothesize that congen-
ital VMs ultimately result from dysregulation of vascular cell MAPK 
and/or PI3K signaling during human embryonic development.
Analysis of multiple different affected tissues in 2 of the 
patients revealed consistency of mutation within an individual, 
confirming a postzygotic hit to a multipotent precursor in those 
Table 2. Genotypic characterization of 15 individuals with MAPK pathway variants and sporadic VMs
Patient 
no.
Age gDNA (hg19) cDNA, aa change Mutant allele 
count
Total allele 
count
Percentage mosaicism by sample origin
1 19 years chr7:g.140453136T>A NM_004333.4: c.1799T>A;  
BRAF p.(V600E)
27 103 FFPE tissue from VM tissue from surgical resection: 26%
Blood: 0%
2 33 years chr12:g.25380275A>C NM_004985.4; NM_033360.3:c.183A>C;  
KRAS p.(Q61H)
114 2241 FFPE tissue from VM tissue from surgical resection of VM: 5%
Blood: 0%
3 12 years chr12:g.25398284G>T NM_004985.4; NM_033360.3: c.35G>T;  
KRAS p.(G12V)
5 174 Fresh skin biopsy from VM: 3%
Blood: 0%
4 24 years chr15: g.66727443 NM_002755.3: c.159_173delTCTTACCCAGAAGCA; 
MAP2K1 p.(F53_Q58delinsL)
44 752 FFPE tissue from VM tissue from surgical resection  
of VM tissue: 6%
5 20 years chr15:g.66727455G>C NM_002755.3: c.171G>C;  
MAP2K1 p.(K57N)
10 136 FFPE tissue from VM tissue from surgical resection: 7%
6 9 years chr15:g.66727456 NM_002755.3: c.173_187delAGAAGGTGGGAGAAC; 
MAP2K1 p.(Q58_E62del)
31 782 FFPE tissue from VM tissue from surgical resection: 4%
Blood: 0%
7A 24 years chr12:g.25398284G>A NM_004985.4; NM_033360.3:  
KRAS c.35G>A; KRAS, p.(G12D)
Multiple  
samples
Cultured fibroblasts from skin biopsy of epidermal nevus: 39%
Fresh skin biopsy of epidermal nevus: 30%
Paraspinal “neurofibroma-like” overgrowth: 30%
8 13 years chr15:g.66727455G>C NM_002755.3: c.171G>C;  
MAP2K1 p.(K57N)
18 992 Fresh skin biopsy: 2%
9 14 years chr12:25398285G>T NM_004985.4; NM_033360.3: c.34G>T;  
KRAS p.(G12C)
23 841 FFPE tissue: 3%
10 18 years chr12:g.25398284G>A NM_004985.4; NM_033360.3: c.35G>A;  
KRAS p.(G12D)
275 7628 Fresh skin biopsy of capillary malformation: 4%
Blood: 0%
11 39 years chr1:g.114713908A>G NM_002524.4:c.182A>G;  
BRAF p.(Q61R)
524 7715 Fresh skin biopsy of VM: 7%
Blood: 0%
Saliva: 0%
12 14 years chr12:g.25398284G>T NM_004985.4; NM_033360.3: c.35G>T;  
KRAS p.(G12V)
193 7105 Fresh skin biopsy of VM: 3%
Blood: 0%
13 7 years chr12:g.25398284G>A NM_004985.4; NM_033360.3: c.35G>A:  
KRAS p.(G12D)
Cultured fibroblasts from skin biopsy  
of capillary malformation: 29%
Blood: 0%
14 10 months chr12:g.25398284G>T KRAS c.35G>T:  
KRAS p.(G12V)
177 3328 Skin biopsy of capillary malformation: 5%
Skin biopsy of epidermal nevus: 13%
15 36 years chr12:g.25398284G>A NM_004985.4; NM_033360.3: c.35G>A:  
KRAS p.(G12D)
200 9510 Affected skin biopsy from left lower limb: 2%
ASee Supplemental Table 5.
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
1 5 0 1jci.org   Volume 128   Number 4   April 2018
mosaic mutations in a third of our AVM cohort, including intracra-
nial AVMs, will radically alter the concept of management of these 
VMs by introducing the possibility of targeted medical therapy.
The cause of the difference in frequency of these variants 
between the high- and low-flow cohorts is not clear. As a minority of 
the low-flow cohort skin biopsies were cultured for fibroblasts before 
DNA extraction, it is possible that the mutations were either lost in 
culture or not present in fibroblasts. We would not, however, expect 
this to explain the size of the difference between the groups, and fur-
ther work will be needed to explore the increased frequency in AVMs.
In summary, these findings demonstrate a cause of sporad-
ic VMs and suggest a common pathogenesis for sporadic VMs 
of different vessel types and at different anatomical locations, 
including intracranial. Genotyping of affected tissue, where 
accessible, should therefore be a key element of management 
across the diverse medical subspecialties to which affected 
patients present. Resulting genetic stratification may not only 
be of value prognostically, but may also now serve to guide 
therapy. Although formal clinical trials will be required before 
routine repurposing of such agents is sanctioned in clinical care, 
Figure 3. Somatic variants in MAP2K1 cluster in exon 2 and are predicted 
to destabilize the 3D structure of the inactive form of the kinase. (A) 
Schematic representation of clustered somatic mutations in exon 2 of 
MAP2K1. (B) Low allele frequency mutations on IGV visualization of deep 
next-generation sequencing data from VM tissue samples of 3 patients. 
(C) 3D structural modelling of an inhibitor-bound (4BM) form (PDB ID: 
3EQG) of MAP2K1 demonstrating the mutated residues. Deletions are 
highlighted in magenta (residues 53–58) and orange (residues 58–62, 
with residue 58 common to both in pink). Critical residue K57, which is 
substituted as a result of the missense mutation, is shown using ball and 
stick representation, with the dashed line indicating a hydrogen-bond 
interaction with the β-sheet of the kinase. Residues involved in interaction 
between helix A and the core kinase domain are also shown.
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licensed targeted medical therapy on a compassionate basis 
may already be considered for severe or life-threatening cases.
Methods
Patient cohorts
Twenty-three patients with AVM, confirmed clinically and radiologi-
cally, who were seen in the Paediatric Dermatology Department at 
Great Ormond Street Hospital for Children, were recruited. At the 
time of recruitment, no genes were known to be causative in sporadic 
AVM. After initial results of our study were available, 2 patients with 
intracranial-only AVM were also recruited for testing via the Paediat-
ric Neurosurgery Department.
In addition, 135 patients with low-flow VMs and/or overgrowth, 
and 1 patient with a high-flow VM were recruited to the Investiga-
tion of Segmental Overgrowth Disorders study (REC 12-EE-0405) 
and found to be WT for a genotype of known sporadic vascular and 
overgrowth-related genes PIK3CA, AKT1, GNAQ, GNA11, and TEK. 
One further patient with a low-flow VM and overgrowth was identified 
after genotyping results from the phase 1 dose-finding trial of ARQ 
092 in children and adults with Proteus syndrome study at the NIH 
(Bethesda, Maryland, USA), bringing the totals of high-flow to 25 and 
low-flow to 135. Detailed clinical phenotyping was undertaken in all 
patients before genotyping (Tables 1 and 2).
DNA extraction
DNA was extracted directly from samples by the DNeasy Blood and Tis-
sue Kit (QIAGEN) and from paraffin-embedded tissue using the Recover-
All Total Nucleic Acid Extraction Kit for FFPE (Thermo Fisher Scientific).
Next-generation sequencing and variant calling
High-flow VM patients. Twenty-one formalin-fixed paraffin-embed-
ded (FFPE) and 4 fresh samples were sequenced using the SureSeq 
Solid Tumour Panel (Oxford Gene Technology). This was chosen 
due to the difficulty in biopsying AVMs due to risk of bleeding and 
because this panel is optimized for FFPE tissue. DNA library prepara-
tion was performed for each sample using the Agilent SureSelect XT 
Reagent Kit per the manufacturer’s protocol (http://www.ogt.co.uk/
Figure 4. Mutations in MAPK pathway–encoding genes lead to activation of downstream signaling and disruption of vascular endothelial tube forma-
tion in vitro. (A and B) Expression of mutant BRAFV600E, MAP2K1K57N, and MAP2K1Q58_E62del in HEK293T cells leads to significantly increased phosphorylation 
of ERK detected by immunoblotting (representative blot shown from duplicate biological replicates), compared with WT gene overexpression and controls. 
Data are shown as mean ± SD. *P < 0.05, 1-way ANOVA. (C) Expression of mutant BRAFV600E and MAP2K1K57N in HUVECs seeded onto Geltrex Matrix leads 
to visible disruption of endothelial vascular tube formation compared with controls. Original magnification, ×50. (D and E) Significant reductions in mean 
number of master junctions, total length of tubes, and total mesh area are indicated by asterisks. Data are shown as mean ± SD. Means were taken from 
triple technical replicates for each of the duplicate biological replicates, standardized to within-replicate controls, and analyzed by 1-way ANOVA with cor-
rection for multiple testing (*P < 0.0167; **P < 0.001).
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
1 5 0 3jci.org   Volume 128   Number 4   April 2018
from paired blood samples. These were sequenced by whole-exome 
sequencing. Library preparation was with SureSelect Agilent QXT v6 
following the manufacturer’s protocol, and sequencing was on the 
HiSeq 3000 (Illumina), with a mean read depth of ×500.
Sequence alignment to the human reference genome (UCSC 
hg19) and variant calling and annotation were performed with our 
in-house pipeline. Briefly, this involves alignment with NovoAlign 
assets/0000/4457/990162_HB_SureSeqSolidTumour_110215.pdf). 
Samples were then pooled and sequenced on a MiSeq instrument (Illu-
mina) according to the manufacturer’s recommendations for paired-
end 150-bp reads. In-depth sequencing was performed to achieve a 
mean sequencing depth of 500 reads for all targeted coding bases.
For 2 further patients, fresh 4 mm skin biopsies were taken from 
the AVM, and DNA was extracted directly from the whole sample and 
Figure 5. BRAF and MAP2K mutations induce VM phenotypes in zebrafish that respond to targeted therapy. (A) Schematic of zebrafish embryos injected with 
Tg (fli1a:GFP) at the 1-cell stage generate zebrafish larvae that are mosaic for the transgene integration and expression. (B) Image of mosaic expression of Tg 
(fli1a:GFP) in a vessel. (C) Images of zebrafish expressing WT or mutant BRAFV600E in a mosaic fashion from a fli1a promoter in endothelial cells. Accumulation of 
blood is visible at the caudal vein vascular plexus in the BRAFV600E–expressing zebrafish and outlined with a dashed red line. (D) Quantification of VM phenotype in 
BRAFWT-expressing (n = 511) and BRAFV600E-expressing (n = 779) zebrafish. (E) BRAFWT and BRAFV600E mosaic expression in stable Tg (fli1a:GFP) larvae to visualize 
all vessels in the zebrafish in the VM lesion. Increased numbers of vascular channels and disorganized architecture of VM lesions are clearly detectable. (F) Sche-
matic of VM treatment protocol and quantification of the percentage of VM BRAFV600E zebrafish with improved blood flow following treatment with vemurafenib. 
VM BRAFV600E zebrafish were randomized prior to DMSO (n = 31) or vemurafenib (n = 19) treatment and blind scored. (G) Images of zebrafish expressing MAPK-
2K1Q58del in a mosaic fashion from a fli1a promoter in endothelial cells (n = 5/37). Zebrafish larvae in D were analyzed by an unpaired parametric t test with Welch’s 
correction and in F by a paired t test comparing matched pairs (before and after treatment). Data are shown as SEM. ***P < 0.001.
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using the Integrative Genomics Viewer (Broad Institute), and mosa-
icism percentage was taken from the mutant allele reads divided by 
the total directly from the BAM. Candidate postzygotic variants were 
confirmed by Sanger sequencing in all DNA samples available from 
each patient. To maximize detection of mutant alleles at low percent-
age mosaicism, restriction enzyme digests of the normal allele were 
designed where necessary using validated methods (51) and Sanger 
sequencing performed. See Supplemental Table 1 for primer sequenc-
es. Touchdown PCR programs were used throughout, with 40 cycles 
for the first PCR (annealing and extension times of 1 minute) and 15 
for the second heminested PCR where required.
Low-flow VM patients. A 4 mm punch biopsy of affected tissue was 
taken from an area of overgrowth and/or VMs. DNA was extracted 
either directly from the biopsy (51/134 patients) or from dermal fibro-
blasts grown from the biopsy (59/134 patients), using the QiaAMP 
DNA Micro Kit (QIAGEN). In 9 of 134 patients, DNA was extracted 
from FFPE tissue samples using the QIAamp DNA FFPE Tissue Kit. In 
cases of facial involvement (15 of 134 patients), a buccal swab served 
as affected tissue, and DNA was extracted via standard methods of 
phenol-chloroform extraction followed by ethanol precipitation. Blood 
and removal of PCR duplicates with Picard Tools followed by local 
realignment around indels and germline variant calling with Hap-
lotypeCaller according to the Genome Analysis Toolkit (GATK) 
best practices. We identified potentially mosaic variants with GATK 
muTECT2 in tumor-only somatic variant calling mode. The raw list 
of single nucleotide variants (SNVs) and indels was then filtered using 
ANNOVAR (http://annovar.openbioinformatics.org). Only exonic and 
donor/acceptor splicing variants were considered. Priority was given 
to rare variants (<1% in public databases, including 1000 Genomes 
project [http://www.internationalgenome.org/], NHLBI Exome Vari-
ant Server [http://evs.gs.washington.edu/EVS/], Complete Genomics 
69 [http://www.completegenomics.com/public-data/69-genomes/], 
and Exome Aggregation Consortium [http://exac.broadinstitute.
org/]). Furthermore, we have an in-house set of approximately 6,000 
exomes encompassing controls, rare diseases for cross-checking any 
shortlisted candidate variants, and for removing sequence artefacts. 
Identification of candidate variants where paired samples were avail-
able was also performed using Ingenuity Variant Analysis (QIAGEN) 
by selecting variants present in skin but not in blood (or in mosaic 
levels in both). For all candidate variants, BAM files were viewed 
Figure 6. Schematic summary of the known and newly identified signaling proteins affected by mosaic mutations that lead to a VM phenotype. Key 
signaling pathways PI3K/AKT/MTOR and RAS/RAF/MEK/ERK control cellular growth, apoptosis, and differentiation through complex transcriptional 
regulation. Multiple receptor types feed into one or both pathways. In addition, there is crosstalk between the 2 pathways at multiple levels (not shown). 
Proteins affected by the genetic mutations presented in this paper are shown in red, with previously identified sites shown in blue. Key classes of poten-
tial targeted therapeutics are shown in green boxes. RTK, receptor tyrosine kinase; GPCR, G protein–coupled receptor.
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nucleotide change (g>c); p.(Q58_E62del) (hereafter termed Q58del) 
is a deletion mutation caused by a deletion of 15 bp. The sequences 
of mutagenesis PCR primers were as follows: K57N-forward: 5′-GAG-
GCCTTTCTTACCCAGAACCAGAAGGTGGG-3′ K57N-reverse: 
5′-CCCACCTTCTGGTTCTGGGTAAGAAAGGCCTC-3′ Q58del-
forward: 5′-CTTACCCAGAAGCTGAAGGATGACGACTTTGAGAA-
GATCAG-3′ Q58del-reverse: 5′-GTCGTCATCCTTCAGCTTCTGGG-
TAAGAAAGGCCTCAAGG-3′. The mutagenesis PCR ran for 15 cycles, 
and each cycle consisted of denaturation at 95°C for 30 seconds, 
annealing at 58°C for 1 minute, and extension at 72°C for 5 minutes.
pDEST26-BRAF. The WT and mutant (p.V600E) human BRAF 
cDNA are in the same Gateway middle entry clones used in a previous 
study (18). These 2 BRAF cDNAs were cloned into the destination vector 
pDEST26 for expression in mammalian cells using the Gateway Clon-
ing System (Invitrogen) according to the manufacturer’s instructions.
HEK293T cell line transfection. HEK293T cells (ATCC, catalog 
CRL-11268) were maintained per established protocols and were 
transfected with mutant and WT cDNA expression plasmids and an 
empty vector control using Lipofectamine 2000. One day before 
transfection, 6 × 105 cells were plated per well of a 6-well culture ves-
sel in 500 μl of growth medium without antibiotics so that cells would 
be 70%–90% confluent at the time of transfection. For each transfec-
tion sample, 4.0 μg plasmid DNA was diluted in 250 μl Opti-MEM I 
Reduced Serum Medium (Thermo Fisher Scientific) and mixed gen-
tly. Lipofectamine 2000 was gently mixed before use; then 10 μl was 
diluted in 250 μl of Opti-MEM I Medium and incubated for 5 minutes 
at room temperature before being combined with the diluted DNA 
(total volume = 500 μl), mixed gently, and incubated for 20 minutes at 
room temperature. Complexes (500 μl) were added to each well con-
taining cells and medium and mixed gently by rocking the plate back 
and forth. Finally, cells were incubated at 37°C in a CO2 incubator for 
30 hours prior to testing for transgene expression.
HUVEC transfection. Based on transfection optimization, HUVECs 
(Thermo Fisher, catalog number C0035C) were incubated in transfec-
tion reagents with a 1:3 DNA/Lipofectamine LTX ratio at 37°C, 5% (v/v) 
CO2 for 48 hours. Volumes described in this section are representative 
of a single well in a 6-well plate. 2.5 μg of either plasmids containing 
the WT or mutated gene of interest (BRAFWT, BRAFV600E, MAP2K1WT, 
MAP2K1K57N, and MAP2K1Q58_E62del as detailed above) or pDest26 empty 
vector or a mock transfection that represented an additional control 
was diluted in 500 μl in Opti-MEM I Reduced Serum Medium with-
out serum (catalog 31985062). Next, 2.5 μl of PLUS Reagent (catalog 
11514015, Thermo Fisher Scientific) was added to the DNA dilution and 
incubated for 10 minutes at room temperature. Transfection complex-
es were formed after adding 7.5 μl Lipofectamine LTX to DNA:PLUS 
Reagent solution (Thermo Fisher Scientific) prior to 30 minutes of incu-
bation at room temperature and then added to a well containing 2 ml 
fresh growth-supplemented medium.
Quantitative real-time PCR
To assess the efficiency of transfection of plasmid DNA in the cells, 
quantitative expression analysis of the genes of interest MAP2K1 and 
BRAF as well as the endogenous control GAPDH was determined by 
real-time qPCR with TaqMan gene expression assays using the Ste-
pOnePlus (Thermo Fisher Scientific) instrument. Standard protocol 
per the manufacturer’s guidelines was followed for Applied Biosys-
tems TaqMan Gene Expression Assay on the StepOnePlus instrument. 
samples were collected where possible, and lymphocyte DNA was 
extracted via the Illustra BACC3 DNA Extraction Kit (GE Healthcare).
Targeted next-generation sequencing was performed on affected 
tissue DNA using a custom panel of overgrowth-related genes on an 
Illumina MiSeq platform. This panel was designed for the low-flow 
study to create a selection of possible candidate genes for overgrowth 
on the basis of the genes/pathways already known to be involved in this 
phenotype. DNA (10 ng) was amplified for 18 cycles of PCR with the 
Ion AmpliSeq custom DNA panel (Thermo Fisher Scientific), enrich-
ing the 195 target amplicons. This included full coverage of all coding 
regions of PIK3CA, PTEN, and CCND2 and hotspot regions in 57 other 
genes (regions of coverage listed in Supplemental Table 2). The panel 
was split into 2 primer pools and amplified with 5× Ion AmpliSeq HiFi 
Master Mix, followed by FuPa treatment (Ion AmpliSeq DNA Library 
Kit 2.0; Thermo Fisher Scientific). The 2 primer pools for each sample 
were then pooled and purified with 1.8× Agencourt AMPure XP mag-
netic beads (Beckman Coulter). Amplicons were 3′ adenylated using 
the NebNext Ultra II End Repair/dA Tailing Module (NEB), followed 
by the NextFlex DNA Barcode adapter (Bio Scientific) ligation using 
the NebNext Ultra II ligation module (NEB). Ligation products were 
purified and size selected using 0.8× Agencourt AMPure XP beads. 
Library concentration was determined with Kapa Biosystems Library 
qPCR quantification kit on the Lightcycler 480 Real-Time PCR Sys-
tem (Roche). Libraries were subsequently diluted to 2 nM and pooled 
in equimolar amounts. Pooled libraries were spiked with 1% PhiX 
DNA (Illumina) and sequenced on the MiSeq desktop sequencer using 
version 2 chemistry at 250 bp read length paired end.
VCF files tailored for mosaic variant calling were created in MiSeq 
Reporter (Illumina) and annotated in Illumina Variant Studio, version 
2.2, resulting in a list of 300–1,000 variants per sample. The program-
ming language R was used to apply hard filters according to the fol-
lowing parameters: read depth greater than 5; quality score greater 
than 10; absence of strand bias (as determined by MiSeq Reporter), 
cross-sample subtraction of artefactual variants called in more than 8 
samples per batch of 24; exonic nonsynonymous variants only. This 
resulted in a list of 1 to 4 candidate variants, the clinical relevance and 
sequencing quality of which were then assessed.
Mosaic variants considered to be causative were confirmed and 
tested in other tissue samples from the same patient alongside DNA 
from healthy controls, either by Sanger sequencing (primers listed in 
Supplemental Table 1) or by custom restriction fragment length poly-
morphism (RFLP). For RFLP, genomic DNA was amplified with Go Taq 
Green (Promega) using the primers listed in Supplemental Table 3. 
The PCR products were designed to include a restriction enzyme rec-
ognition site allowing specific digestion of the mutant allele, while 
leaving the WT allele intact. The digested PCR fragments were then 
mixed with GeneScan 500 LIZ Size Standard (Applied Biosystems) 
and loaded on an ABI3730 capillary sequencer. The area under the 
curve of undigested/digested DNA was used to calculate the mutation 
burden using GeneMapper v5.0 software (Applied Biosystems).
Mutant plasmid construction and HEK293T and HUVEC transfection
pCMV6-MAP2K1. The pCMV6-MAP2K1 plasmid for in vivo expression 
in mammalian cells was ordered from Origene (ID: SC118424). To gen-
erate mutant MAP2K1 expression vector, an improved QuikChange 
site-directed mutagenesis protocol was used (Agilent Technologies) 
(52). p.(K57N) is a predicted missense alteration caused by a single 
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BRAFWT, BRAFV600E, MAP2K1WT, or MAP2K1Q58del cDNA were recom-
bined with the fli1a promoter in p5Efli1a2.2k and the pDestTol2CG2 
expression vector using the Tol2kit Gateway cloning method (53), 
resulting in fli1a-BRAFWT, fli1a-BRAFV600E, fli1a-MAP2K1WT, and fli1a-
MAP2K1Q58del constructs. Mixed fli1a-BRAF (1 nl) or fli1a-MAP2K1 
plasmid DNA and Tol2 mRNA (37 ng/μl and 35 ng/μl, respectively) 
were injected into the 1-cell stage of fli1a:GFP zebrafish embryos (Spe-
cies Danio rerio, AB line) (54). Embryos were raised at 28.5°C and 
screened for phenotypes. Embryos were then fixed in 4% PFA.
Drug treatments
Zebrafish embryos were treated with the BRAF inhibitor vemurafenib 
(PLX4032). Embryos were incubated with 0.1 μM of the drug from 2.5 
days post fertilization (dpf) after initial imaging, which was refreshed 
daily. Control embryos were incubated in E3 with DMSO at the same 
concentration as drug used. During live imaging, embryos were kept 
in 1:5,000 MS222 and 1.5% LMP agar. Leica stereo brightfield micros-
copy was used for live color imaging. Fluorescence images were taken 
using Leica Sp5 confocal microscopy. Images were processed using 
FIJI (ImageJ). GraphPad Prism was used to analyze data.
Statistics
Western blot data (Figure 4, A and B) were analyzed using 1-way ANOVA 
comparing mock transfection to WT and mutant allele groups for each 
mutant tested. Densitometry data were pooled from biological repli-
cates and used to calculate means and SDs. P < 0.05 was used at a 95% 
CI. Angiogenesis data (Figure 4, D and E) were analyzed using 1-way 
ANOVA comparing mock transfection controls to WT and mutant allele 
groups for each mutant tested. An initial 1-way ANOVA was undertaken 
to demonstrate that biological replicates were significantly different, and 
therefore data between replicates were first standardized to the within-
experiment control before being pooled for analysis of standardized 
means and SD. Correction for multiple testing was applied after ANOVA, 
reducing the P value to less than 0.0167 at a CI of 95%. For zebrafish 
data, significance was assessed for Figure 5D using unpaired parametric 
t test with Welch’s correction and for Figure 5F using paired t test.
Study approval
These studies were conducted according to Declaration of Helsinki 
principles and were approved by the local Research Ethics Commit-
tees of each center involved (London Bloomsbury, London, United 
Kingdom; University of Cambridge, Cambridge, United Kingdom; 
and University of Edinburgh, Edinburgh, United Kingdom). All partic-
ipants provided written informed consent. Separate written informed 
consent was obtained for publication of all clinical photographs. All 
zebrafish work was done in accordance with United Kingdom Home 
Office Animals (Scientific Procedures) Act (1986) and approved by the 
University of Edinburgh Ethical Review Committee.
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ing of the low- and high-flow cohorts, HEK293T cell work, and fig-
ure preparation. PS was responsible for the HUVEC work and figure 
preparation. KAA and VEP were responsible for patient recruitment 
and phenotyping of the low-flow cohort. RK, GC, and WB contrib-
uted to sequencing and cell culture maintenance. KD, ZZ, and EEP 
Probes used for quantitative analysis were as follows: MAP2K1 (assay 
ID: Hs00983247_g1), BRAF (assay ID: Hs00269944_m1), and GAP-
DH (assay ID: Hs02786624_g1) (all from Life Technologies). Results 
of the quantitative gene expression levels were obtained after the 
amplification reaction using StepOne software (version 2.3). Results 
are based on analysis of 2 biological replicates, with triplicate technical 
replicates in each experiment, and quantitative values of the Ct aver-
aged. The relative expression of the genes of interest was determined 
by calculating the ratio of their expression compared with that of the 
GAPDH endogenous control in the same sample.
Western blotting
Cell lysates were prepared using standard protocols. Primary and 
secondary antibodies are shown in Supplemental Table 4. The West-
ern blot basic protocol was as follows: following heating at 95°C in 2× 
Laemmli sample buffer in 5% β-mercaptoethanol, 40 μg of protein was 
run on 4%–20% Mini-PROTEAN TGX Precast Protein Gels (catalog 
4561096, Bio-Rad). The transfer was blocked at room temperature for 
1 hour in 5% dry milk or 5% BSA dissolved in TBS–0.05% Tween 20 
(TBST). The transfer was incubated with primary antibody (1:1,000 
dilution in 3% BSA, BSA in 1× TBST) at room temperature overnight. 
The membrane was then washed 3 times for 15 minutes in TBST. Incu-
bation with the secondary antibody was conducted at room tempera-
ture for 1 hour. As a secondary antibody, we used anti-rabbit RB96 in 
1:7,000 dilution and diluted in 3% BSA (BSA in 1× TBST) or 3% milk.
Endothelial cell tube formation assay and microscopy
Cells and all reagents in this subsection were obtained from Invitrogen 
unless otherwise stated. The formation of endothelial tubes by HUVECs 
(Thermo Fisher, catalog C0035C) on growth factor–reduced Geltrex 
(catalog A1413202) was conducted according to the manufacturer’s pro-
tocol (catalog MAN0001687) using Medium 200PRF supplemented 
with Low Serum Growth Supplement (Thermo Fisher Scientific). Briefly, 
24-well culture plates were coated with 100 μl/well (50 μl/cm2) Geltrex 
and incubated for 30 minutes at 37°C. After harvesting transfected and 
untreated HUVECs (P2) cultured on 6-well plates, cells were seeded on 
coated plates at a density of 4.5 × 104/cm2 (9 × 104 cells/well) in 200 μl/
cm2 (400 μl/well) supplemented with 200PRF medium and cultured in 
a CO2 incubator (37°C, 5% [v/v] CO2, 95% humidity). Thirty minutes 
before the end of the incubation period, cells were treated with 2 μg/
ml (0.8 μl/well) calcein AM (catalog C3099) and incubated at 37°C, 
5% (v/v) CO2. Tube formation observed at the 14-hour time point was 
imaged with a 5× objective lens of an Olympus IX71 inverted fluores-
cence and bright field microscope using HCImage software. The degree 
of tube formation was assessed by measuring all aspects of tubule, node, 
and mesh growth in triplicate, using randomly chosen fields from each 
well using the angiogenesis analyzer for ImageJ (NIH).
Transgenic zebrafish
A zebrafish fli1a promoter was generated by gateway PCR with prim-
ers (forward: 5′-GGGGACAACTTTGTATAGAAAAGTTGCCTG-
GCTGTCAAGCTCCAGC-3′, reverse: GGGGACTGCTTTTTTGTA-
CAAACTTGATATGTGGCGGAGAGACAGAG-3′; promoter-specific 
sequences are underlined). The promoter comprises 2.2 kb immedi-
ately upstream of the first ATG of the fli1a gene. The PCR product was 
then cloned into the gateway 5′ donor vector pDONRP4-P1R to obtain 
the 5′ entry clone p5Efli1a2.2k. Middle entry clones containing human 
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